Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the present invention relates to dihydropteridinones of general Formula (I), wherein the groups L, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and their use in cancer therapy.
• the groups L, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and their use in cancer therapy.
• Polo-like kinases are serine/threonine kinases that play important roles in regulating processes in the cell cycle.
• PLKs There are four PLKs disclosed in the state of the art, i.e. PLK-1, PLK-2, PLK-3 and PLK-4.
• PLKs play a role in the regulation of the eukaryotic cell cycle (e.g. regulation of the mitotic machinery in mammalian cells).
• PLK-1 a central role with respect to the regulation of mitosis is shown (Glover et al. 1998 , Genes Dev. 12:3777-87; Qian et al. 2001 , Mol Biol Cell. 12:1791-9). Overexpression of PLK-1 seems to be strongly associated with neoplastic cells including cancers (WO 2004/014899). Overexpression of PLK1 has been documented for various tumor types such as non-small cell lung cancer, squamous cell carcinomas, breast, ovary or papillary carcinomas as well as colorectal cancers (Wolf et al. 1997 , Oncogene 14, pages 543-549; Knecht et al. 1999 , Cancer Res.
• the invention relates to the use of compounds of Formula (I), wherein
• the present invention relates to the use of a compound of Formula (I) according to the invention, wherein the compound is selected from the group consisting of the compounds of Formula (I) shown in the following Table Config.
• the compound is selected from the group consisting of the compounds of Formula (I) shown in the following Table Config.
• the abbreviations X 1 , X 2 , X 3 , X 4 and X 5 used in the Table in each case denote a link to a position in the general Formula shown in the Table instead of the corresponding groups R 1 , R 2 , R 3 , R 4 and L-R 5 .
• the invention relates to the use of a compound of Formula (I) according to the invention, wherein the polo-like kinase is PLK-1.
• the invention relates to the use of a compound of Formula (I) according to the invention, wherein the disease is characterized by inappropriate cellular proliferation, migration, apoptosis or angiogenesis, preferably by inappropriate cellular proliferation.
• Inappropriate cell proliferation means cellular proliferation resulting from inappropriate cell growth, from excessive cell division, from cell division at an accelerated rate and/or from inappropriate cell survival.
• the invention relates to the use of a compound of Formula (I) according to the invention, wherein the disease is cancer selected from the group consisting of carcinomas, sarcomas, melanomas, myelomas, hematological neoplasias, lymphomas and childhood cancers.
• cancer selected from the group consisting of carcinomas, sarcomas, melanomas, myelomas, hematological neoplasias, lymphomas and childhood cancers.
• carcinomas within the scope of the invention include but are not limited to adenocarcinoma (AC), squamous cell carcinoma (SCC) and mixed or undifferentiated carcinomas.
• Carcinomas within the scope of the invention include but are not limited to the following histologies:
• sarcomas within the scope of the invention include but are not limited to Ewing-sarcoma, osteosarcoma or osteogenic sarcoma, chondrosarcoma, synovial sarcoma, leiomyosarcoma, rhabdomyosarcoma, mesothelial sarcoma or mesothelioma, fibrosarcoma, angiosarcoma or hemangioendothelioma, liposarcoma, glioma or astrocytoma, myxosarcoma, malignant fibrous histiocytoma, mesenchymous or mixed mesodermal tumour, neuroblastoma and clear cell sarcoma.
• melanomas within the scope of the invention include but are not limited to superficial spreading melanoma, nodular and lentigo-maligna melanoma.
• myelomas within the scope of the invention include but are not limited to immunocytoma, plasmocytoma and multiple myeloma.
• the invention relates to the use according to the invention, wherein the hematological neoplasia is leukemia.
• hematologic neoplasias within the scope of the invention include but are not limited to acute or chronic leukemias of myeloid, erythroid or lymphatic origin, myelodysplastic syndromes (MDS) and myeloproliferative syndromes (MPS, such as chronic myelogeneous leukemia, osteomyelofibrosis, polycythemia vera or essential thrombocythemia).
• MDS myelodysplastic syndromes
• MPS myeloproliferative syndromes
• lymphomas within the scope of the invention include but are not limited to:
• the invention relates to the use according to the invention, wherein the disease is cancer selected from the group consisting of mixed tumours, undifferentiated tumours and metastases thereof.
• mixed tumours within the scope of the invention include but are not limited to adenosquamous carcinomas, mixed mesodermal tumours, carcinosarcomas and teratocarcinomas.
• undifferentiated, other tumours or metastases thereof within the scope of the invention include but are not limited to undifferentiated tumours, carcinomas of unknown primary (CUP), metastases of unknown primary (MUP) and pheochromocytoma, carcinoids.
• the invention relates to the use of a compound of Formula (I) according to the invention, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of autoimmune disorders selected from the group consisting of amyloidosis, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic sclerosis (scleroderma), mixed connective tissue disease, Sjögren's syndrome, ankylosing spondylitis, autoimmune vasculitis, Behcet's syndrome, psoriasis, autoimmune arthritis, sarcoidosis and diabetes mellitus.
• autoimmune disorders selected from the group consisting of amyloidosis, systemic l
• the invention relates to the use of a compound of Formula (I) according to the invention, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of fungous diseases including but not limited to candidiasis, cryptococcosis, aspergillosis, mucormycosis, tinea, dermatophytosis, histoplasmosis, blastomycosis, coccidiosis, pneumocystis.
• fungous diseases including but not limited to candidiasis, cryptococcosis, aspergillosis, mucormycosis, tinea, dermatophytosis, histoplasmosis, blastomycosis, coccidiosis, pneumoc
• Homologous genes encoding polo-like kinases have been identified from various eukaryotes ranging from fungi ( S. cerevisiae, S. pombe, C. albicans ), fly ( D. melanogaster ), worms ( C. elegans ) and vertebrates and represent a central mechanism to regulate mitotic progression (Glover et al. 1996, J Cell Biol, 135, pages 1681-1684, Bachewich et al. 2003, Mol Biol Cell 14, pages 2163-2180).
• the preferentially local or systemic administration of a therapeutically effective amount of a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof, represents a novel approach for treating fungous diseases.
• the invention relates to a method for treating a disease characterized by abnormal cell proliferation in a human or non-human mammalian body comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof.
• a compound of Formula (I) optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof.
• the invention relates to a method for treating patients who suffer from one or more diseases cited above comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof.
• a compound of Formula (I) optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof.
• a method for treating a disease characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators in a mammal comprises regulating, modulating, binding or inhibiting PLK activity and/or overexpression of PLK or one of the other PLK isoforms, preferably PLK-1
• the invention relates to the use of a compound of Formula (I) according to the invention, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof, wherein the active ingredient is administered orally, enterically, transdermally, intravenously, peritoneally or by injection, preferably intravenously.
• a compound of Formula (I) inhibits the proliferation of various human tumor cell lines including but not limited to Saos-2, H4, MDA-MB-435S, MDA-MB453, MCF7, HeLa S3, HCT116, Colo 205, HT29, FaDu, HL-60, K-562, THP-1, HepG2, A549, NCI-H460, NCI-H520, GRANTA-519, Raji, Ramos, BRO, SKOV-3, BxPC-3, Mia CaPa-2, DU145, PC-3, NCI-N87, MES-SA, SK-UT-1B and A431.
• the Alamar BlueTM assay is designed to measure quantitatively the proliferation of cells by incorporating a fluorometric/colorimetric growth indicator based on the detection of metabolic activity.
• the various human tumor cell lines can be purchased from American Type Culture Collection (ATCC) or the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultivated in 75 to 175 cm 2 tissue culture flasks in the medium indicated by the supplier. The cells are maintained at 37° C. and 5% CO 2 in a humidified atmosphere, with an appropriate split ratio. Logarithmically growing cells are used for the assays.
• ATCC American Type Culture Collection
• DSMZ German Collection of Microorganisms and Cell Cultures
• Assay conditions On day one of the experiment 1000-4000 cells (in 100 ⁇ l medium) are seeded into each well of a sterile 96-well plate. The number of cells used is dependent on the growth rate and size of the cells. Eight wells on each plate are left free to accommodate for controls (4 wells for medium plus reduced AlamarBlueTM, and 4 wells for medium plus oxidized AlamarBlueTM). The plates are kept in the incubator overnight. On day two of the experiment serial dilutions of the inhibitor are prepared in medium containing 0.1% DMSO. Typical concentrations used are 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003 and 0.001 ⁇ M.
• Propidium iodine (PI) binds stoichiometrically to double stranded DNA and thus is a suitable agent to measure the DNA content of cells in order to determine the percentage of cells residing in various cell cycle stages (G0/1-, S- and G2/M-phases), whereas cells in G0 or G1 phase do have a diploid DNA content (2N) cells in G2 and M-phase (mitosis) do have a doubled (4N) DNA content.
• the various human tumor cell lines can be purchased from American Type Culture Collection (ATCC) or the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultivated in 75 to 175 cm 2 tissue culture flasks in the medium indicated by the supplier. The cells are maintained at 37° C. and 5% CO 2 in a humidified atmosphere, with an appropriate split ratio. Logarithmically growing cells are used for the assays.
• ATCC American Type Culture Collection
• DSMZ German Collection of Microorganisms and Cell Cultures
• Assay conditions On day one of the experiment 1 ⁇ 10 6 tumor cells are plated in 15 ml medium onto each 75 cm 2 tissue culture flask and the cultures are returned to the incubator. On the next day serial twofold dilutions (100 ⁇ concentrated) of the inhibitor are prepared in tissue culture medium containing 10% DMSO. 150 ⁇ l of the 100 ⁇ concentrated dilution is added to the 15 ml medium in the flask. As control DMSO is given into a separate flask to yield a final concentration of 0.1%. Typical final concentrations used are 1.6, 08, 0.4, 0.2, 0.1, 0.05, 0.025, 0.0125, 0.00625 ⁇ M in medium containing 0.1% DMSO.
• test tubes 15 ml test tubes (Falcon) with 5 ml of 80% cold ethanol are prepared and the cell suspension is added slowly and kept for at least 2 h or overnight at minus 20° C. Fixed cells are pelleted, washed once with PBS and the cell pellet is then resuspended in 2 ml of 0.25% Triton X-100 in PBS. After 5 min incubation on ice, 5 ml of PBS is added to each sample and the sample is again centrifuged at 1000 rpm for 5 min at 4° C.
• PI propidium iodine
• Analysis of the DNA content of the cells can be performed using a FACS analyzer equipped with an argon laser (500 mW, emission 488 nm) and the use of the DNA Cell Quest analysis software (Beckton Dickinson). The logarithmic PI fluorescence is determined in a band-pass filter (Beckton Dickinson 585/43). Quantification of the cell populations residing in the individual cell cycle phases (e.g. G0/G1-, S- and G2/M-phases) is done with the ModFit LT software package from Becton Dickinson. An EC 50 value for cells arrested at the G2/M-phase of the cell cycle is calculated by using a sigmoidal curve analysis program (Graph Pad Prism version 3.03).
• a compound of Formula (I), its tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, may be used on their own or combined with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
• Suitable pharmaceutical preparations for the use in accordance with the invention include, for example, tablets, capsules, suppositories, solutions, and particularly solutions for injection (s.c., i.v., i.m.) and infusion, syrups, emulsions or dispersible powders.
• the amount of pharmaceutically active compound in each case should be in the range from 0.1-90 wt. %, preferably 0.5-50 wt. % of the total composition, i.e. in amounts which are sufficient to achieve the dosage range given below.
• the doses specified may, if necessary, be given several times a day.
• Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
• excipients for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
• excipients for example inert dilu
• Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
• the core may also consist of a number of layers.
• the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
• Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
• a sweetener such as saccharin, cyclamate, glycerol or sugar
• a flavour enhancer e.g. a flavouring such as vanillin or orange extract.
• suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
• Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as the diluent organic solvents may optionally be used as solubilisers or auxiliary solvents, and transferred into injection vials or ampoules or infusion bottles.
• preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants
• solubilisers or auxiliary solvents may optionally be used as solubilisers or auxiliary solvents, and transferred into injection vials or ampoules or infusion bottles.
• Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
• Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
• Suitable excipients may be, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica and silicates), sugar (e.g. glucose, lactose and dextrose), emulsifiers (e.g.
• paraffins e.g. petroleum fractions
• oils of vegetable origin e.g. groundnut or sesame oil
• mono- or polyfunctional alcohols e.g. ethanol or glycerol
• carriers such as e.g. natural mineral powders (e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica
• lignin e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone
• lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate.
• the preparations are administered in the usual way, preferably by oral or transdermal route, particularly preferably by oral route.
• the tablets may, of course, contain additives, such as e.g. sodium citrate, calcium carbonate and dicalcium phosphate together with various additives, such as starch, preferably potato starch, gelatine and the like, in addition to the abovementioned carriers.
• Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to form tablets.
• the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
• solutions of the active substances may be prepared using suitable liquid carrier materials.
• the dosage for intravenous use is 1-2000 mg per hour, preferably between 5-1000 mg per hour.
• the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
• the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
• the ampoules contain 5 mg, 25 mg and 50 mg of active substance.
• Example 1 Active substance 2 mg/ml Hydrochloric acid 6.8 ⁇ l 1N NaCl 0.009 g/ml WFI (water for 1 ml injection) ad pH 4.5 mOsmol/kg 295
• Example 2 Active substance 10.0000 g Hydrochloric acid 36.6735 g 1N NaCl 45.000 g WFI 4934.8265 g pH 4.3 mOsmol/kg 300
• Example 3 Active susbtance 500 mg Hydrochloric acid 1.6 ml 1N NaCl 450.0 mg WFI ad 50 ml pH 4.0 mOsmol/kg 290
• Example 4 Active susbtance 0.5 mg Hydrochloric acid 1.705 ⁇ l 1N NaCl 9 mg WFI ad 1 ml pH 4.8 mOsmol/kg 285
• Example 5 Active susbtance 1 mg Hydrochloric acid 3.6125 ⁇ l 1N NaCl 0.009 g WFI ad 1 ml pH 4.8
• a compound of Formula (A1) is reacted with a compound of Formula (A2) to obtain a compound of Formula (A3) (Diagram 1A).
• This reaction may be carried out according to WO 00/43369 or WO 00/43372.
• Compound (A1) is commercially obtainable, for example, from City Chemical LLC, 139 Allings Crossing Road, West Haven, Conn., 06516, USA.
• Compound (A2) may be prepared by procedures known from the literature: (a) F. Effenberger, U. Burkhart, J. Willfahrt Liebigs Ann. Chem. 1986, 314-333; (b) T. Fukuyama, C.-K. Jow, M. Cheung, Tetrahedron Lett.
• Step 1A 1 equivalent of the compound (A1) and 1 to 1.5 equivalents, preferably 1.1 equivalents of a base, preferably potassium carbonate, potassium hydrogen carbonate, sodium carbonate or sodium hydrogen carbonate, calcium carbonate, most preferably potassium carbonate, are stirred in a diluent optionally mixed with water, for example acetone, tetrahydrofuran, diethylether, cyclohexane, petroleum ether or dioxane, preferably cyclohexane or diethylether.
• a base preferably potassium carbonate, potassium hydrogen carbonate, sodium carbonate or sodium hydrogen carbonate, calcium carbonate, most preferably potassium carbonate
• Step 2A The compound obtained in Step 1A (A3) is reduced at the nitro group and cyclised to form the compound of Formula (A4) (Diagram 2A).
• Step 2A 1 equivalent of the nitro compound (A3) is dissolved in an acid, preferably glacial acetic acid, formic acid or hydrochloric acid, preferably glacial acetic acid, and heated to 50 to 70° C., preferably about 60° C. Then a reducing agent, for example zinc, tin or iron, preferably iron filings, is added to complete the exothermic reaction and the mixture is stirred for 0.2 to 2 hours, preferably 0.5 hours, at 100 to 125° C., preferably at about 117° C. After cooling to ambient temperature the iron salt is filtered off and the solvent is distilled off.
• an acid preferably glacial acetic acid, formic acid or hydrochloric acid, preferably glacial acetic acid
• a reducing agent for example zinc, tin or iron, preferably iron filings
• the residue is taken up in a solvent or mixture of solvents, for example ethyl acetate or dichloromethane/methanol 9/1 and semisaturated NaCl solution, and filtered through kieselgur, for example.
• the organic phase is dried and evaporated down.
• the residue (compound (A4)) may be purified by chromatography or by crystallisation or used as the crude product in Step 3A of the synthesis.
• Step 2A (A4) may be reacted by electrophilic substitution as shown in Diagram 3A to obtain the compound of Formula (A5).
• Step 3A 1 equivalent of the amide of Formula (A4) is dissolved in an organic solvent, for example dimethylformamide or dimethylacetamide, preferably dimethylacetamide, and cooled to about ⁇ 5 to 5° C., preferably 0° C.
• organic solvent for example dimethylformamide or dimethylacetamide, preferably dimethylacetamide
• 0.9 to 1.3 equivalents of sodium hydride and 0.9 to 1.3 equivalents of a methylating reagent, e.g. methyl iodide, are added.
• the reaction mixture is stirred for 0.1-3 hours, preferably about 1 hour, at about 0 to 10° C., preferably at about 5° C., and may optionally be left to stand for a further 12 hours at this temperature.
• the reaction mixture is poured onto ice water and the precipitate is isolated.
• the residue (compound (A5)) may be purified by chromatography, preferably over silica gel, or by crystallisation, or used as the crude product in step 4A of the synthesis.
• the amination of the compound (A5) obtained in Step 3A to yield the compound of Formula (A9) may be carried out using the methods known from the literature, for variants 4.1 A from e.g. (a) M. P. V. Boarland, J. F. W. McOmie J. Chem. Soc. 1951, 1218-1221 or (b) F. H. S. Curd, F. C. Rose J. Chem. Soc. 1946, 343-348, for variants 4.2 A from e.g. (a) Banks J. Am. Chem. Soc. 1944, 66, 1131, (b) Ghosh and Dolly J. Indian Chem. Soc. 1981, 58, 512-513 or (c) N. P. Reddy and M. Tanaka Tetrahedron Lett. 1997, 38, 4807-4810.
• 1 equivalent of the compound (A5) and 1 to 3 equivalents, preferably about 2 equivalents of the compound (A6) are heated without a solvent or in an organic solvent such as for example sulpholane, dimethylformamide, dimethylacetamide, toluene, N-methylpyrrolidone, dimethylsulphoxide or dioxane, preferably sulpholane, for 0.1 to 4 hours, preferably 1 hour, at 100 to 220° C., preferably at about 160° C.
• the product (A9) is crystallised by the addition of organic solvents or mixtures of solvents, e.g. diethylether/methanol, ethyl acetate, methylene chloride, or diethylether, preferably diethylether/methanol 9/1, or purified by chromatography.
• a solvent for example toluene or dioxane and combined with a phosphine ligand, for example 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl and a palladium catalyst, for example tris(dibenzylidene-acetone)-dipalladium(0) and a base, for example caesium carbonate, and refluxed for 1-24 h, preferably 17 h.
• the reaction mixture is purified for example over silica gel and the product (A8) is isolated from the solution or obtained by suitable crystallisation.
• the product (A8) is dissolved in a suitable solvent, for example dioxane and mixed with acid, for example semiconcentrated hydrochloric acid, for example in the ratio of solvent to acid of 3:1. Then the mixture is refluxed for 1-48 h, for example 12 h, and the precipitate formed is isolated. If desired the product (A9) is purified by crystallisation. Step 5A
• 1 equivalent of the compound (A9) is dissolved with 1 equivalent of an activating reagent, e.g. O-benzotriazolyl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and a base, for example 1.5 equivalents of diisopropylethylamine (DIPEA) in an organic diluent, for example dichloromethane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethylacetamide, preferably dichloromethane or dimethylformamide.
• an activating reagent e.g. O-benzotriazolyl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU)
• DIPEA diisopropylethylamine
• organic diluent for example dichloromethane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidon
• the compounds of general Formula (I) may be synthesised analogously to the following examples of synthesis.
• the numbering of the Examples corresponds to the numbering used in Table 2. These Examples are, however, intended only as examples of procedures to illustrate the invention further, without restricting the invention to their subject matter.
• Example 188 To synthesise the compounds Example 188 and Example 203 of Table 2, first of all an intermediate compound Z2 is prepared as described below.
• D-alanine methyl ester ⁇ HCl 50.0 g (0.36 mol) D-alanine methyl ester ⁇ HCl is suspended in 500 mL of dichloromethane and 35 mL of acetone and combined with 30.0 g (0.37 mol) of sodium acetate and 80.0 g (0.38 mol) of sodium triacetoxyborohydride. The mixture is stirred for 12 h and then poured onto 400 mL of 10% sodium hydrogen carbonate solution. The organic phase is dried over Na 2 SO 4 and evaporated down.
• the compounds may be prepared according to the following references: (a) S. Schuetz et al. Arzneistoff - Anlagen 1971, 21, 739-763, (b) V. M. Belikov et al. Tetrahedron 1970, 26, 1199-1216 and (c) E. B. Butler and McMillan J. Amer. Chem. Soc. 1950, 72, 2978.
• trans-dibenzyl-4-morpholino-cyclohexylamine may be prepared by the following method:
• the cis isomer may be prepared analogously.
• the cis isomer may be prepared analogously.
• the cis isomer may be prepared analogously.
• the faster eluting cis compound crystallised from ethyl acetate.
• the trans-compound is crystallised from ethanol+concentrated HCl. Yield: 8.5 g (61%) cis-isomer and 2.2 (13%) trans-isomer.
• the trans-isomer may be prepared analogously.
• Example 232 60 mg of the compound of Example 232 is dissolved in 10 mL ethyl acetate and stirred with 1 mL of acetic anhydride and 1 mL of triethylamine for 30 min. at RT. The solvent is eliminated in vacuo, the residue combined with water and ammonia, the crystals precipitated are suction filtered and washed with water and a little cold acetone.
• the residue is taken up in 20 mL dichloromethane, stirred with 0.5 g of thiomorpholine and 0.5 g of NaBH(OAc) 3 for 12 h at RT. Then water and potassium carbonate are added, the organic phase is separated off, dried and the solvent is eliminated in vacuo. The residue is purified over a silica gel column. The appropriate fractions are evaporated down in vacuo and the hydrochloride is precipitated with ethereal HCl.

Landscapes

• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Biomedical Technology (AREA)
• Diabetes (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Rheumatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Transplantation (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Obesity (AREA)
• Communicable Diseases (AREA)
• Endocrinology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Emergency Medicine (AREA)
• Cardiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=34926179

Family Applications (2)

Family Applications After (1)

Country Status (18)

Cited By (40)

Families Citing this family (14)

Citations (3)

Family Cites Families (50)

• 2005
  • 2005-07-25 US US11/188,926 patent/US20060074088A1/en not_active Abandoned
  • 2005-08-09 EP EP05770942.0A patent/EP1778240B1/fr active Active
  • 2005-08-09 RU RU2007109109/15A patent/RU2406503C2/ru not_active IP Right Cessation
  • 2005-08-09 AU AU2005274387A patent/AU2005274387B2/en not_active Ceased
  • 2005-08-09 CN CN201410065809.2A patent/CN104055778A/zh active Pending
  • 2005-08-09 ES ES19168693T patent/ES2975234T3/es active Active
  • 2005-08-09 NZ NZ553722A patent/NZ553722A/en not_active IP Right Cessation
  • 2005-08-09 ES ES05770942T patent/ES2800308T3/es active Active
  • 2005-08-09 KR KR1020077005855A patent/KR101283378B1/ko not_active IP Right Cessation
  • 2005-08-09 KR KR1020137009370A patent/KR101353990B1/ko not_active IP Right Cessation
  • 2005-08-09 WO PCT/EP2005/008626 patent/WO2006018185A2/fr active Application Filing
  • 2005-08-09 PL PL19168693.0T patent/PL3560499T3/pl unknown
  • 2005-08-09 CN CNA2005800277121A patent/CN101022809A/zh active Pending
  • 2005-08-09 EP EP19168693.0A patent/EP3560499B1/fr active Active
  • 2005-08-09 BR BRPI0513977-5A patent/BRPI0513977A/pt not_active IP Right Cessation
  • 2005-08-09 MX MX2012004012A patent/MX343697B/es unknown
  • 2005-08-09 MX MX2007001851A patent/MX2007001851A/es active IP Right Grant
  • 2005-08-09 JP JP2007526350A patent/JP2008509949A/ja not_active Withdrawn
  • 2005-08-09 CA CA2575787A patent/CA2575787C/fr not_active Expired - Fee Related
  • 2005-08-09 EP EP11185693A patent/EP2409706A1/fr not_active Withdrawn
  • 2005-08-12 TW TW094127427A patent/TWI360420B/zh not_active IP Right Cessation
  • 2005-08-12 AR ARP050103378A patent/AR050694A1/es unknown
• 2007
  • 2007-01-10 ZA ZA200700281A patent/ZA200700281B/xx unknown
  • 2007-02-13 IL IL181304A patent/IL181304A/en not_active IP Right Cessation
• 2008
  • 2008-05-15 US US12/120,740 patent/US8058270B2/en active Active
• 2012
  • 2012-07-05 JP JP2012151593A patent/JP2012211178A/ja active Pending
• 2013
  • 2013-08-07 IL IL227841A patent/IL227841A/en not_active IP Right Cessation

Patent Citations (8)

Also Published As

Similar Documents

Legal Events